[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595433":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":24,"responsibleParty":43,"collaborators":47,"id":51,"slug":18,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":18,"enrollmentInfo":60,"targetDuration":18,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":26,"whyStopped":18,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Polypill","EXPERIMENTAL","The polypill combines DAPT and a high intensity statin: (a) aspirin 81 mg, (b) rosuvastatin (40 or 10 mg) and (c) prasugrel 10 mg or clopidogrel 75 mg.",[13],"Combination Product: Polypill",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual care","NO_INTERVENTION","Participants in the usual care arm will be prescribed DAPT and statins as standard therapy in individual pills.",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":18},"COMBINATION_PRODUCT","The polypill is an inert capsule designed to combine multiple individual medications into a convenient, once-daily pill. In this case it will include DAPT and a statin.",[9],[25],{"facility":5,"status":26,"city":27,"state":28,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Dallas","Texas","75209","United States",{"type":32,"coordinates":33},"Point",[34,35],-96.80667,32.78306,{"lat":35,"lon":34},[38],{"name":39,"role":40,"phone":41,"phoneExt":18,"email":42},"Ambarish Pandey, MD","CONTACT","214-645-9868","ambarish.pandey@utsouthwestern.edu",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Ambarish Pandey","Associate Professor",[48],{"name":49,"class":50},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100595433",false,"NCT07032389","A Polypill for Acute Coronary Syndrome","Polypill Strategy for the Treatment of Patients After Acute Coronary Syndromes - A Multicenter Randomized Controlled Trial","PolyACS","Inclusion Criteria:\n\n* Age ≥ 18\n* Hospitalization for acute coronary syndrome with percutaneous coronary intervention\n* Discharged on aspirin, prasugrel or clopidogrel, and a high-intensity statin\n\nExclusion Criteria:\n\n* Current need for systemic anticoagulation\n* Contraindication to receive any components of the polypill\n* History of allergic reaction or intolerance to aspirin, prasugrel or clopidogrel, or rosuvastatin\n* Comorbidities that might be expected to limit lifespan within the 12-month study period\n* Increased risk of bleeding or planned urgent surgery that would necessitate use of DAPT for \\\u003C 12 months\n* Inability to provide written informed consent\n* Pregnancy","ALL","18 Years",{"count":61,"type":62},1000,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2","The current study aims to investigate whether combining the standard medications prescribed after acute coronary syndrome (ACS)-aspirin, P2Y12 inhibitors, and statins-into a single polypill can improve outcomes following an ACS event. Although these therapies are effective, gaps in adherence and uptake significantly contribute to risk or adverse events in the post-ACS period. This study is designed as a pragmatic, multi-center, randomized trial to assess the feasibility and effectiveness of a polypill-based strategy for treatment of ACS.",[68],"Acute Coronary Syndrome",[68,9,70],"Adherence","2026-01-16",{"date":73,"type":74},"2026-01-20","ACTUAL",{"date":76,"type":74},"2025-12-05",{"date":78,"type":62},"2029-08-01",{"name":5,"class":6},1]